Bispecific antibodies and their applications

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Bispecific antibodies (BsAbs) are engineered proteins recognizing two distinct epitopes, enabling dual targeting capabilities.
• The clinical success of approved BsAbs like catumaxomab and blinatumomab highlights their therapeutic potential.
• Over 60 BsAb formats have been developed, with many progressing through clinical trials.

Purpose of the Study:

• To review the diverse formats of bispecific antibodies.
• To summarize the clinical applications of bispecific antibodies.
• To discuss strategies for optimizing bispecific antibody design.

Main Methods:

• Literature review of bispecific antibody formats.
• Analysis of clinical applications and trial data.
• Synthesis of design optimization strategies.

Main Results:

• Identification of numerous bispecific antibody formats and their specific applications.
• Demonstration of bispecific antibodies in redirecting T cells, blocking signaling pathways, and targeted payload delivery.
• Highlighting key milestones in bispecific antibody development and clinical progression.

Conclusions:

• Bispecific antibodies represent a rapidly advancing field with broad therapeutic potential.
• Optimized design strategies are crucial for enhancing the efficacy and safety of bispecific antibodies.
• The diverse formats and applications of bispecific antibodies are transforming targeted therapies.